Values First Advisors Inc. Acquires 1,419 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Values First Advisors Inc. lifted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 18,412 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,419 shares during the quarter. Values First Advisors Inc.’s holdings in Collegium Pharmaceutical were worth $711,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of COLL. Pacer Advisors Inc. increased its position in shares of Collegium Pharmaceutical by 31.8% in the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock valued at $109,749,000 after acquiring an additional 821,541 shares during the last quarter. Rubric Capital Management LP increased its position in shares of Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after acquiring an additional 499,473 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Collegium Pharmaceutical by 411.1% in the second quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock valued at $11,661,000 after acquiring an additional 291,286 shares during the last quarter. LSV Asset Management increased its position in shares of Collegium Pharmaceutical by 188.7% in the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after acquiring an additional 248,751 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Collegium Pharmaceutical by 8.2% in the second quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock valued at $54,124,000 after acquiring an additional 128,003 shares during the last quarter.

Analyst Upgrades and Downgrades

COLL has been the topic of a number of recent analyst reports. Piper Sandler reissued a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright boosted their price target on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Finally, Truist Financial boosted their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Trading Down 4.4 %

Shares of COLL stock opened at $34.31 on Friday. The company has a current ratio of 1.11, a quick ratio of 1.04 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.12 billion, a P/E ratio of 14.30 and a beta of 0.94. The stock has a 50 day simple moving average of $37.67 and a 200 day simple moving average of $35.38. Collegium Pharmaceutical, Inc. has a 1 year low of $20.95 and a 1 year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.22. The business had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.13 earnings per share. On average, research analysts predict that Collegium Pharmaceutical, Inc. will post 5.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now directly owns 53,816 shares in the company, valued at $1,970,741.92. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the transaction, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.